Catalyst

Slingshot members are tracking this event:

Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AMGN Community voting in process
Euronext Brussels: UCB Community voting in process

Additional Information

Additional Relevant Details Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME). These data showed FRAME met the co-primary endpoints by reducing the incidence of new vertebral fracture through months 12 and 24 in postmenopausal women with osteoporosis treated with romosozumab. The study also met the secondary endpoint of reducing the incidence of clinical fractures (composite of vertebral and non-vertebral fractures) in postmenopausal women with osteoporosis through 12 months. However, the secondary endpoint of reducing the incidence of non-vertebral fractures through months 12 and 24 was not met.
http://www.amgen.com...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 21, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Positive Top-line, Vertebral Fracture, Placebo-controlled Fracture Study